ArticleSurgical endoscopy2026
Single-incision robotic complete mesocolic excision for right-sided colon neoplasms: technical and oncologic feasibility.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSingle-incision robotic surgery (SIRS) using the da Vinci SP system (dVSP) offers advantages such as improved cosmesis, reduced invasiveness, and technical precision in colorectal surgery. However, real-world data regarding the technical feasibility and oncologic outcomes of dVSP-based complete mesocolic excision (CME) with central vascular ligation (CVL) for right-sided colon neoplasms remain limited.
methodsWe retrospectively reviewed the medical records of patients who underwent single-incision robotic right colectomy for colon cancer or precancerous lesions with dVSP between July 2019 and April 2025. Demographic characteristics, perioperative outcomes, pathologic results, and survival outcomes were analyzed.
resultsFifty-two patients were included. Mean operation time and estimated blood loss were 282.2 ± 54.5 min and 65.9 ± 44.9 ml, respectively. Intracorporeal anastomosis was performed in 67.3% of cases, and the mean umbilical wound length was 3.7 ± 0.9 cm. There were no conversions to open surgery or intraoperative complications. The mean time to first flatus was 2.6 ± 0.7 days, and patients began a soft diet at 3.2 ± 0.6 days postoperatively, with a mean hospital stay of 7.0 ± 2.4 days. Postoperative complications occurred in 19.2% and readmission rate was 5.8%. Pathologic outcomes showed 23.9% of patients with stage III disease, the mean number of harvested lymph nodes was 45.5 ± 25.0, and all cases had negative resection margins. One patient (1.9%) developed local recurrence at 8 months postoperatively, resulting in disease-specific mortality, and another patient (1.9%) developed multiple lung metastases at 9 months and is currently receiving palliative chemotherapy. Among patients with malignant tumors, 5-year overall survival and disease-free survival rates were 93.3% and 93.7%, respectively. The median follow-up period was 30.0 (range 5.0-72.0) months.
conclusionSingle-incision robotic right colectomy using the dVSP is technically feasible and safe approach, offering favorable perioperative results and has proven oncologic safety based on long-term outcomes.
Indexed as
Identifiers
41703038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.